

Anti-Cancer Drugs 2009

Author Index to Volume 20

- Aaron DuVall G *et al.* Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer, 89
- Abdalla S. *See* Chakrabarti R, 334
- Abe A and Yamada H. Harmol induces apoptosis by caspase-8 activation independently on Fas/Fas ligand interaction in human lung carcinoma H596 cells, 373
- Abreu JG. *See* Amado NG, 543
- Agheli A *et al.* Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma, 525
- Agra N. *See* Carrillo J, 527
- Airolidi M. *See* Milla P, 396
- Akashi K. *See* Makiyama A, 123
- Alali FQ. *See* Mhaidat MN, 601
- Al-Ashry MS. *See* Salah-Eldin MA, 191
- Alessi B. *See* Minisini AM, 503
- Alexandre J. *See* Mir O, 105
- Alm K. *See* Myhre L, 230
- Alonso J. *See* Carrillo J, 527
- Al-sawalha NA. *See* Mhaidat MN, 601
- Altieri V. *See* Di Lorenzo G, 277
- Al-Wadei HA *et al.* Prevention of pancreatic cancer by the beta-blocker propranolol, 477
- Al-Wadei MH. *See* Al-Wadei HA, 477
- Amado NG *et al.* Isoquercitrin isolated from *Hyptis fasciculata* reduces glioblastoma cell proliferation and changes β -catenin cellular localization, 543
- Amadori D. *See* Vannini I, 918
- Ambergen TA. *See* Beijer S, 625
- Anderton J. *See* Rukazekov Y, 856
- Andreetta C. *See* Minisini AM, 503
- Annerau J-P. *See* Kruczynski A, 364
- Anzenbacher P. *See* Mašek V, 305
- Anzenbacherová E. *See* Mašek V, 305
- Aoun N. *See* Baz W, 508
- Apra P. *See* Facchini G, 893
- Aprile G *et al.* Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer, 217
- Areguian J. *See* Martel-Frchet V, 469
- Arita S. *See* Makiyama A, 123
- Arnesen T. *See* Takubo K, 668
- Asai K. *See* Kimura T, 513
- Autorino R. *See* Di Lorenzo G, 277
- Baba E. *See* Makiyama A, 123
- Bagnardi V. *See* Balduzzi A, 197
- Bailly C. *See* Kruczynski A, 364
- Balduzzi A *et al.* Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features, 197
- Ball S. *See* Friedman L, 444
- Barret J-M. *See* Kruczynski A, 364
- Baumann P *et al.* Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001, 259
- Baz W *et al.* A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors, 508
- Beauparlant P *et al.* Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777, 346
- Bédard D. *See* Beauparlant P, 346
- Bednarski PJ. *See* Hamberger J, 559
- Beijer S *et al.* Effect of adenosine 5'-triphosphate infusions on the nutritional status and survival of preterminal cancer patients, 625
- Bekaii-Saab T. *See* Friedman L, 444
- Benesch M *et al.* Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study, 794
- Bennetzen MV. *See* Yde CW, 723
- Bergamini L. *See* Bianchi G, 616
- Bernier C. *See* Beauparlant P, 346
- Bertolini F. *See* Balduzzi A, 197
- Bertucci F. *See* Gonçalves A, 946
- Bianchi G *et al.* Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer, 616
- Biersack B. *See* Knauer S, 676
- Bijman MNA *et al.* Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines, 450
- Blanc M. *See* Martel-Frchet V, 469
- Bloomer WD. *See* Papadopoulos MV, 493
- Boeck S. *See* Schulz C, 867
- Bordier V. *See* Némati F, 932
- Bordin V. *See* Ferrari D, 185
- Boumendjel A. *See* Martel-Frchet V, 469
- Boven E. *See* Bijman MNA, 450
- Boxberger F. *See* Wolff K, 165
- Bozzoni S. *See* Ferrari D, 185
- Brabec V. *See* Mašek V, 305
- Bracht K. *See* Hamberger J, 559
- Bras-Gonçalves R. *See* Némati F, 932
- Braun D. *See* Hamberger J, 559
- Brel V. *See* Kruczynski A, 364
- Bremner JB. *See* Locke JM, 822
- Bria E. *See* Nisticò C, 109
- Brigliadori G. *See* Vannini I, 918
- Britt-Marie F. *See* Josefine P, 7
- Brückl V. *See* Wolff K, 165
- Buchholz S. *See* Seitz S, 553
- Burgess K. *See* Lim SH, 461
- Burton J. *See* Baz W, 508
- Caldiera S. *See* Ferrari D, 185
- Cao C. *See* Li M, 941
- Cao C-X. *See* Chen P, 141
- Cao J. *See* Zhang L, 416
- Cao W *et al.* Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer, 287
- Cao X. *See* Oshima T, 312
- Caponigro F *et al.* Docetaxel in the management of head and neck cancer, 639
- Caraglia M. *See* Facchini G, 893
- Cardillo A. *See* Balduzzi A, 197
- Carlioni S. *See* Vannini I, 918
- Carpino A. *See* Nisticò C, 109
- Carrier MK. *See* Guzmán EA, 149
- Carrillo J *et al.* Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth, 527
- Carteni G. *See* Di Lorenzo G, 277
- Cattel L. *See* Milla P, 396
- Cebula B. *See* Janus A, 693
- Celtikci B *et al.* Methotrexate-induced apoptosis is enhanced by altered expression of methylenetetrahydrofolate reductase, 787
- Cerqueira DM. *See* Amado NG, 543
- Chakrabarti R *et al.* Tranilast inhibits the growth and metastasis of mammary carcinoma, 334
- Chan H. *See* Beauparlant P, 346
- Chapelier A. *See* Némati F, 932
- Charafe-Jauffret E. *See* Gonçalves A, 946
- Chatta G. *See* Lara Jr PN, 179
- Chaudhary U. *See* Turner J, 215
- Chen DJ and Huerta S. Smac mimetics as new cancer therapeutics, 646
- Chen H *et al.* Dihydroartemisinin inhibits growth of pancreatic cancer cells *in vitro* and *in vivo*, 131
- Chen L. *See* Sun Y, 607
- Chen P *et al.* Anticancer activity of PDSS2, prenyl diphosphate synthase, subunit 2, in gastric cancer tissue and the SGC7901 cell line, 141
- Chen T-M. *See* Yu S-T, 382
- Chen W. *See* Tian G, 389
- Chen X. *See* Sun Y, 757
- Chen Y-H. *See* Yu S-T, 382
- Cheng J. *See* Li M, 941
- Chern J-W. *See* Yu S-T, 382
- Choi J. *See* Hwang JJ, 815
- Choi J-S. *See* Shin S-C, 584
- Choi YH. *See* Jin C-Y, 713
- Chu Y-L. *See* Chen P, 141
- Clausen MP. *See* Yde CW, 723
- Clingan PR. *See* Locke JM, 822
- Codecà C. *See* Ferrari D, 185
- Cognetti F. *See* Nisticò C, 109
- Colleoni M. *See* Balduzzi A, 197
- Cox BF. *See* Luo Y, 483
- Cui X *et al.* Reversal effects of hyaluronan oligosaccharides on adriamycin resistance of K562/A02 cells, 800
- Cuppone F. *See* Nisticò C, 109
- Curt P. *See* Josefine P, 7

- Dagnelie PC. *See* Beijer S, 625
 Dalzell JR and Samuel LM. The spectrum of 5-fluorouracil cardiotoxicity, 79
 Daniel C. *See* Némati F, 932
 Davies BR. *See* Rukazenzov Y, 856
 De Cremoux P. *See* Némati F, 932
 de Graeff A. *See* Beijer S, 625
 de Pinieux G. *See* Némati F, 932
 De Placido S. *See* Di Lorenzo G, 277
 Deblock M. *See* Gonçalves A, 946
 Decaudin D. *See* Némati F, 932
 Dedes I. *See* Dedes KJ, 321
 Dedes KJ *et al.* Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities, 321
 Delsol G. *See* Kruczyński A, 364
 Deray G. *See* Launay-Vacher V, 81
 Di Lorenzo G *et al.* Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients, 277
 Di Maria G. *See* Ferrari D, 185
 Diaio DM. *See* Zhang YK, 702
 Dinter D. *See* Kripp M, 75
 Dittrich C. *See* Lentz F, 97
 Dong G-Z. *See* Terai K, 901
 Dong Q. *See* Li D, 59
 Doria F. *See* Di Lorenzo G, 277
 Drescher A. *See* Lentz F, 97; *also* Milla P, 396
 Duivenvoorden WC. *See* Foroodi F, 115
 Durand J-P. *See* Mir O, 105
- Ebrahim MA. *See* Salah-Eldin MA, 191
 Effenberger K. *See* Knauer S, 676
 Efferth T. *See* Ramacher M, 910
 El-Soueiidi R. *See* Baz W, 508
 Elstad NL. *See* Aaron DuVall G, 89
 Erben P. *See* Horisberger K, 519
 Essapen S. *See* Modjtahedi H, 851
 Esterni B. *See* Gonçalves A, 946
 Eussen SR. *See* Beijer S, 625
 Evans CP. *See* Lara Jr PN, 179
 Extra J-M. *See* Gonçalves A, 946
- Fabbri F. *See* Vannini I, 918
 Facchini G *et al.* New treatment approaches in renal cell carcinoma, 893
 Fahy J. *See* Kruczyński A, 364
 Faiella A. *See* Di Lorenzo G, 277
 Fasola G. *See* Minisini AM, 503
 Fedier A. *See* Dedes KJ, 321
 Feng M. *See* Zhao JG, 281
 Fernández N. *See* Carrillo J, 527
 Ferrari D *et al.* A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer, 185
 Ferraris E. *See* Porta C, 409
 Ferro M. *See* Di Lorenzo G, 277
 Fink D. *See* Dedes KJ, 321
 Fiore F. *See* Facchini G, 893
 Fiore J. *See* Ferrari D, 185
 Fleischhack G. *See* Benesch M, 794
 Floriani I. *See* Ferrari D, 185
 Foa P. *See* Ferrari D, 185
 Fontaine J-J. *See* Némati F, 932
 Fournier M. *See* Nisticò C, 109
 Foroodi F *et al.* Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells, 115
 Forte F. *See* Baz W, 508
 Fournier E. *See* Kruczyński A, 364
- Fowers KD. *See* Aaron DuVall G, 89
 Fox GB. *See* Luo Y, 483
 Franke D. *See* Baumann P, 259
 Friedman L *et al.* Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells, 444
 Frost DJ. *See* Luo Y, 483
 Fu Z. *See* Wang C, 534
 Fuchs J. *See* Friedman L, 444
 Fujimura T. *See* Fushida S, 752
 Fushida S *et al.* Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases, 752
- Gabizon A. *See* Grenader T, 15; *also* Grenader T, 845
 Gagne GD. *See* Luo Y, 483
 Gamble AB. *See* Locke JM, 822
 Gandara DR. *See* Lara Jr PN, 179
 Gao C *et al.* In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells, 807
 Garofalo A. *See* Oshima T, 312
 Gehl J. *See* Linnert M, 157
 Geng M. *See* Cao W, 287
 Gennatas K. *See* Michalaki V, 204
 Gennatas S. *See* Michalaki V, 204
 Gianni L. *See* Bianchi G, 616
 Gilabert M. *See* Gonçalves A, 946
 Gilbert K. *See* Beauparlant P, 346
 Glazar AI. *See* LaBarbera DV, 425
 Goldberg A. *See* Grenader T, 15; *also* Grenader T, 845
 Goldhirsch A. *See* Balducci A, 197
 Goldwasser F. *See* Mir O, 105
 Gonçalves A *et al.* Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status, 946
 Gonnella A. *See* Di Lorenzo G, 277
 Gordon GB. *See* Luo Y, 483
 Goudarzi A. *See* Heravi M, 659
 Goulet D. *See* Beauparlant P, 346
 Grande F. *See* Oshima T, 312
 Gratton M-O. *See* Beauparlant P, 346
 Gray PD. *See* LaBarbera DV, 425
 Grenader T *et al.* Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel, 845; *also*. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas, 15
 Grénman S. *See* Miettinen S, 267
 Grinev VV. *See* Ramanouskaya TV, 573
 Grossman D. *See* LaBarbera DV, 425
 Growcott JW. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054, 83
 Gu Y. *See* Terai K, 901
 Guan Y. *See* He J, 838
 Gudmar L. *See* Josefine P, 7
 Guerra B. *See* Sandholt IS, 238; *also* Yde CW, 723
 Gunasekera SP. *See* Guzmán EA, 149
 Guo W. *See* Zhang XY, 926
 Guo X. *See* Cui X, 800
 Guzmán EA *et al.* Selective cytotoxic activity of the arine-derived batzelline compounds against pancreatic cancer cell lines, 149
- Hadas-Halperin I. *See* Grenader T, 15
 Hagemeyer H. *See* Baumann P, 259
 Hahn EG. *See* Wolff K, 165
 Halmos G. *See* Seitz S, 553
 Hamberger J *et al.* Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents, 559
 Hamilton G. *See* Hamberger J, 559
 Harper MK. *See* LaBarbera DV, 425
 Hartinger CG. *See* Lentz F, 97
 Hartmann JT. *See* Pintoff J, 73
 He J *et al.* Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in the greatest dimension, 838
 He Q. *See* Zhang L, 416
 Heinemann V. *See* Schulz C, 867
 Henke M. *See* Lentz F, 97
 Henrik H. *See* Josefine P, 7
 Heravi M *et al.* Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule, 659
 Hilger RA. *See* Lentz F, 97
 Hirano G. *See* Makiyama A, 123
 Hirata K. *See* Kimura T, 513
 Hochhaus A. *See* Horisberger K, 519; *also* Kripp M, 75
 Hoffheinz R-D. *See* Horisberger K, 519; *also* Kripp M, 75
 Hohenberger W. *See* Wolff K, 165
 Hohla F. *See* Seitz S, 553
 Horbach T. *See* Wolff K, 165
 Horger M. *See* Pintoff J, 73
 Horisberger K *et al.* Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer, 519
 Hose CD. *See* Monks A, 682
 Hou K. *See* Li D, 59; *also* Zhang Y, 208
 Houvenaeghel G. *See* Gonçalves A, 946
 Hradil VP. *See* Luo Y, 483
 Hu C. *See* Zhang L, 416
 Hu X. *See* Zhang Y, 208
 Hu Y. *See* Zhang L, 416
 Huang C-J. *See* Agheli A, 525
 Huerta S. *See* Chen DJ, 646
 Hupperets PS. *See* Beijer S, 625
 Huq A *et al.* The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells, 21
 Hwang JJ *et al.* A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways, 815
 Hyun Y-L. *See* Hwang JJ, 815
- Iaffaioli RV. *See* Facchini G, 893
 Imarisio I. *See* Porta C, 409
 Imbert T. *See* Kruczyński A, 364
 Imbimbo C. *See* Di Lorenzo G, 277
 Imesch P. *See* Dedes KJ, 321
 Ionna F. *See* Caponigro F, 639
 Ireland CM. *See* LaBarbera DV, 425
 Isobe T. *See* Makiyama A, 123
 Issinger O-G. *See* Sandholt IS, 238
 Izzo F. *See* Nisticò C, 109

- Jacquemier J. *See* Gonçalves A, 946
 Jaehde U. *See* Milla P, 396
 James E *et al.* Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature, 634
 Jang S. *See* Hwang JJ, 815
 Janmaat ML. *See* Bijman MNA, 450
 Janus A *et al.* Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinoside cytarabine, 693
 Jaradat SA. *See* Mhaidat MN, 601
 Jean-Claude BJ. *See* Heravi M, 659
 Ji Y *et al.* Combined treatment with TNF- α /gefitinib alleviates the resistance to gefitinib in PC-9 cells, 832
 Jiang H. *See* Chen H, 131; *also* Zhang M, 355
 Jiang J. *See* Cao W, 287
 Jiang M. *See* He J, 838
 Jin C-Y *et al.* Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage, 713
 Jin Y. *See* Cao W, 287
 Jing W. *See* Zhang Y, 208
 Johansson MC. *See* Myhre L, 230
 Johnson JD. *See* Guzmán EA, 149
 Josefine P *et al.* Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia, 7
 Jothy S. *See* Chakrabarti R, 334
 Judde J-G. *See* Némati F, 932
 Jukka K. *See* Josefine P, 7

 Kaehler G. *See* Horisberger K, 519
 Kaiser M. *See* Hamberger J, 559
 Kanz L. *See* Pintoff J, 73
 Kaur M. *See* LaBarbera DV, 425
 Keppler BK. *See* Lentz F, 97
 Kim C-S. *See* Hwang JJ, 815
 Kim G-Y. *See* Jin C-Y, 713
 Kim MJ. *See* Hwang JJ, 815
 Kim W-J. *See* Jin C-Y, 713
 Kim YS. *See* Hwang JJ, 815
 Kimura T *et al.* Plasma concentration of amrubicin in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities, 513
 Kinoshita J. *See* Fushida S, 752
 Kjeld S. *See* Josefine P, 7
 Knauer S *et al.* Melanoma-specific ferrocene esters of the fungal cytotoxin illudin M, 676
 Kok M. *See* Bijman MNA, 450
 Kondapaka S. *See* Monks A, 682
 Kotasek D. *See* Singhal N, 953
 Koti I. *See* Syrigou E, 1
 Kripp M *et al.* Alpha-fetoprotein expressing metastatic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin, 75
 Kropshofer G. *See* Benesch M, 794
 Kruczynski A *et al.* Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase, 364
 Kudoh S. *See* Kimura T, 513
 Kurimasa A. *See* Takubo K, 668

 Kusaba H. *See* Makiyama A, 123
 Kuwada SK. *See* LaBarbera DV, 425
 Kwon TK. *See* Jin C-Y, 713
 Kyoh S. *See* Kimura T, 513

 LaBarbera DV *et al.* The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells, 425
 Laferriere N. *See* Bianchi G, 616
 Lamarca A. *See* Martel-Frchet V, 469
 Lara Jr PN *et al.* A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study, 179
 Lassay L. *See* Benesch M, 794
 Latera J. *See* Li Y, 770
 Lathia C. *See* Bianchi G, 616
 Launay-Vacher V and Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies, 81
 Laurent-Puig P. *See* Némati F, 932
 Lavoie M. *See* Beuparlant P, 346
 Lawrance AK. *See* Celtikci B, 787
 Lee HB. *See* Lim SH, 461
 Lee J-H. *See* Hwang JJ, 815
 Lee JS. *See* Hwang JJ, 815
 Lee SJ. *See* Jin C-Y, 713
 Lentz F *et al.* Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study, 97
 Li C. *See* Friedman L, 444
 Li D *et al.* PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells, 59
 Li H. *See* Cao W, 287
 Li JM. *See* Zhang YK, 702
 Li L. *See* Liu H, 41
 Li M *et al.* A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer, 941; *also see* Zhang XY, 926
 Li P-K. *See* Friedman L, 444
 Li X-q. *See* Liu H, 41
 Li Y *et al.* Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms, 770; *also see* Woodall CE, 437
 Lialiaris TS *et al.* Antineoplastic and cytogenetic effects of chlorpromazine on human lymphocytes *in vitro* and on Ehrlich ascites tumor cells *in vivo*, 746
 Lian Yan X. *See* Zhang XY, 926
 Liebeck M. *See* Hamberger J, 559
 Lim SH *et al.* New cytotoxic rosamine derivatives selectively accumulate in the mitochondria of cancer cells, 461
 Lin G. *See* Wang C, 534
 Lin J. *See* Friedman L, 444
 Lin L. *See* Friedman L, 444
 Lin Y-J and Zhen Y-S. Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice, 65
 Lindauer A. *See* Lentz F, 97
 Linke A. *See* Janus A, 693
 Linnert M and Gehl J. Bleomycin treatment of brain tumors: an evaluation, 157
 Liu A. *See* Cui X, 800
 Liu H *et al.* Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A 431 cells and lung carcinoma H460 cells, 41
 Liu J. *See* Tian G, 389; *also* Tian G, 403
 Liu QH. *See* Woodall CE, 437
 Liu T. *See* LaBarbera DV, 425
 Liu X-j. *See* Liu H, 41
 Liu Y. *See* Li D, 59; *also* Zhang Y, 208
 Livartowski A. *See* Némati F, 932
 Locke JM *et al.* Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate, 822
 Loibl S. *See* Bianchi G, 616
 Longmate J. *See* Lara Jr PN, 179
 Longo F. *See* Caponigro F, 639
 Longo N. *See* Di Lorenzo G, 277
 Lou G. *See* Cao W, 287
 Louie S. *See* Oshima T, 312
 Lowry J. *See* Baz W, 508
 Lu C. *See* Li M, 941
 Lu R. *See* Wang C, 534
 Lu W. *See* Gao C, 807
 Lu Y-H. *See* Tang C, 249
 Lu Y-j. *See* Ji Y, 832
 Luciani A. *See* Ferrari D, 185
 Lukan N. *See* Kripp M, 75
 Luo Y *et al.* ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature, 483
 Lv J-q. *See* Wang C, 534
 Lykkesfeldt AE. *See* Yde CW, 723

 Ma S-I. *See* Ji Y, 832
 Ma T. *See* Cao W, 287
 Machová M. *See* Mašek V, 305
 Makiyama A *et al.* Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines, 123
 Makrilia N. *See* Syrigou E, 1
 Mancuso P. *See* Balduzzi A, 197
 Mandl-Weber S. *See* Baumann P, 259
 Männlein G. *See* Wolff K, 165
 Marchand A. *See* Kruczynski A, 364
 Marit H. *See* Josefine P, 7
 Mark Hickinson D. *See* Rukazenzov Y, 856
 Marra L. *See* Facchini G, 893
 Marshall G. *See* Rukazenzov Y, 856
 Martel-Frchet V *et al.* Investigation of a new 1,3-diarylpropanone as a potential antimitotic agent targeting bladder carcinoma, 469
 Martin I. *See* Mir O, 105
 Martin RCG. *See* Woodall CE, 437
 Mascarenhas D. *See* Huq A, 21
 Mašek V *et al.* Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450, 305
 Matalka II. *See* Mhaidat MN, 601
 Matalqah SM. *See* Mhaidat MN, 601
 Mayer F. *See* Pintoff J, 73
 Mayer P. *See* Kruczynski A, 364
 Mayo MS. *See* Watkins JF, 294
 Mazzer M. *See* Aprile G, 217
 Meeker T. *See* Huq A, 21
 Mehta RS. *See* Raj KP, 301
 Meier C. *See* Wolff K, 165
 Meisinger I. *See* Pintoff J, 73
 Mendes da Silva JF. *See* Amado NG, 543
 Menezes FS. *See* Amado NG, 543

- Menis J. *See* Minisini AM, 503
Meyer CI. *See* Guzmán EA, 149
Mhaidat MN *et al.* Inhibition of MEK sensitizes paclitaxel-induced apoptosis of human colorectal cancer cells by downregulation of GRP78, 601
Michalaki V *et al.* Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results, 204
Miettinen S *et al.* Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure, 267
Miettinen S and Ylikomi T. Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy, 589
Milius W. *See* Knauer S, 676
Milla P *et al.* Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity, 396
Minisini AM *et al.* Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era, 503
Mir O *et al.* Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience, 105
Mirone V. *See* Di Lorenzo G, 277
Mitsuoka S. *See* Kimura T, 513
Modjtahedi H and Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities, 851
Modzelewska K. *See* LaBarbera DV, 425
Moghal N. *See* LaBarbera DV, 425
Monforte J. *See* Monks A, 682
Monks A *et al.* Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts, 682
Montagna E. *See* Balduzzi A, 197
Montheil V. *See* Mir O, 105
Moon S-K. *See* Jin C-Y, 713
Morgan SJ. *See* Luo Y, 483
Moroso S. *See* Aprile G, 217
Mourelatos C. *See* Lialiaris TS, 746
Mouritsen OG. *See* Yde CW, 723
Muanza TM. *See* Heravi M, 659
Muessle B. *See* Horisberger K, 519
Müller H. *See* Benesch M, 794
Myhre L *et al.* Normal-like breast cells, but not breast cancer cells, recovered from treatment with N', N''-diethylnorspermine, 230
Nakano S. *See* Makiyama A, 123
Nakhl F. *See* Baz W, 508
Neamati N. *See* Oshima T, 312
Némati F *et al.* Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts, 932
Neto VM. *See* Amado NG, 543
Nexø BA. *See* Nissen KK, 174
Nissen KK *et al.* Association of a single nucleotide polymorphic variation in the human chromosome 19q13.3 with drug responses in the NCI60 cell lines, 174
Nisticò C *et al.* Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity, 109
Niu Y-Y. *See* Chen P, 141
Oh E-T. *See* Terai K, 901
Ohta T. *See* Fushida S, 752
Olsen BB. *See* Sandholt IS, 238
Olśzewski U. *See* Hamberger J, 559
Oredsson SM. *See* Myhre L, 230
Orlando L. *See* Balduzzi A, 197
Ortmann O. *See* Seitz S, 553
Oshima T *et al.* Combination effects of SC144 and cytotoxic anticancer agents, 312
Ostermeier N. *See* Wolff K, 165
Oyama K. *See* Fushida S, 752
Paglino C. *See* Porta C, 409
Palmieri G. *See* Di Lorenzo G, 277
Pan H. *See* Li M, 941
Pan J. *See* Gao C, 807
Pan S. *See* Chen H, 131; *also* Zhang M, 355
Pannitteri G. *See* Petronelli A, 880
Papachristou F. *See* Lialiaris TS, 746
Papadia A. *See* Seitz S, 553
Papadopoulou MV and Bloomer WD. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore, 493
Park C. *See* Jin C-Y, 713
Park CY. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis, 848
Park HJ. *See* Terai K, 901
Park M-T. *See* Terai K, 901
Park SC. *See* Agheli A, 525
Parnis FX. *See* Singhal N, 953
Pascoletti G. *See* Minisini AM, 503
Peña C. *See* Bianchi G, 616
Pennanen PT *et al.* Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models, 51
Perdonà S. *See* Di Lorenzo G, 277
Perri F. *See* Caponigro F, 639; *also* Facchini G, 893
Pestaña Á. *See* Carrillo J, 527
Petersen KD. *See* Monks A, 682
Petronelli A *et al.* Triterpenoids as new promising anticancer drugs, 880
Pezzoli P. *See* Monks A, 682
Piga A. *See* Minisini AM, 503
Pignata S. *See* Facchini G, 893
Pintoff J *et al.* Long-term disease stabilization during second-line gemcitabine in a refractory metastatic haemangioendothelioma, 73
Pisano C. *See* Facchini G, 893
Pitts TP. *See* Guzmán EA, 149
Porta C *et al.* Sorafenib tosylate in advanced kidney cancer: past, present and future, 409
Posadas E. *See* Lara Jr PN, 179
Post S. *See* Horisberger K, 519
Poupon M-F. *See* Némati F, 932
Prud'homme GJ. *See* Chakrabarti R, 334
Puglisi F. *See* Aprile G, 217; *also* Minisini AM, 503
Qian H and Yang Y. Alterations of cellular organelles in human liver-derived hepatoma G2 cells induced by adriamycin, 779
Qin B. *See* Makiyama A, 123
Qiu F. *See* Zhao JG, 281
Qu X. *See* Li D, 59; *also* Zhang Y, 208
Quinn DI. *See* Lara Jr PN, 179
Raab G. *See* Bianchi G, 616
Rachid Z. *See* Heravi M, 659
Radzioch D. *See* Heravi M, 659
Rahim R and Strobl JS. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells, 736
Raj KP *et al.* Need for a new treatment strategy: leptomeningeal carcinomatosis from gastric cancer, 301
Ramacher M *et al.* Effect of artesunate on immune cells in *ret*-transgenic mouse melanoma model, 910
Ramanouskaya TV *et al.* Relationship between structure and antiproliferative, proapoptotic, and differentiation effects of flavonoids on chronic myeloid leukemia cells, 573
Ranson M. *See* Locke JM, 822
Rescigno P. *See* Di Lorenzo G, 277
Reulbach U. *See* Wolff K, 165
Rick F. *See* Seitz S, 553
Ro S. *See* Hwang JJ, 815
Robak T. *See* Janus A, 693
Rong Cui J. *See* Zhang XY, 926
Ronot X. *See* Martel-Franchet V, 469
Ropert S. *See* Mir O, 105
Rory Goodwin C. *See* Li Y, 770
Rosen EM. *See* Li Y, 770
Rosenberg SH. *See* Luo Y, 483
Rosengren RJ. *See* Somers-Edgar TJ, 33
Roulston A. *See* Beauparlant P, 346
Rozen R. *See* Celtikci B, 787
Rukazenkoy Y *et al.* Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?, 856
Rutkowski S. *See* Benesch M, 794
Ryoke K. *See* Takubo K, 668
Saif MW. *See* James E, 634; *also* Syrigou E, 1
Salah-Eldin MA *et al.* Phase II study of capecitabine plus cisplatin in patients with gastric cancer, 191
Salvagni S. *See* Bianchi G, 616
Samuel LM. *See* Dalzell JR, 79
Sanati H. *See* Raj KP, 301
Sandholt IS *et al.* Resorufin: a lead for a new protein kinase CK2 inhibitor, 238
Sang Y. *See* Li Y, 770
Sarvilinna NS. *See* Pennanen PT, 51
Scarano E. *See* Balduzzi A, 197
Schally AV. *See* Seitz S, 553
Scheulen ME. *See* Lentz F, 97
Schlisser A. *See* Heravi M, 659
Schmidmaier R. *See* Baumann P, 259
Schobert R. *See* Knauer S, 676
Schuller HM. *See* Al-Wadei HA, 477
Schulz C *et al.* UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?, 867
Schwab SA. *See* Wolff K, 165
Sehested M. *See* Monks A, 682

- Seidel RH. *See* Aaron DuVall G, 89
- Seitz S *et al.* Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition, 553
- Shao W. *See* He J, 838
- Shibata Y. *See* Makiyama A, 123
- Shin S-C and Choi J-S. Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats, 584
- Shiota G. *See* Takubo K, 668
- Shoemaker RH. *See* Monks A, 682
- Siegler N. *See* Benesch M, 794
- Siena S. *See* Bianchi G, 616
- Simopoulou M. *See* Lialiaris TS, 746
- Singh B. *See* Huq A, 21
- Singh G. *See* Foroodi F, 115
- Singhal N *et al.* Response to erlotinib in a patient with treatment refractory chordoma, 953
- Smith HJ. *See* Watkins JF, 294
- Smolewski P. *See* Janus A, 693
- Smolnykova VV. *See* Ramanouskaya TV, 573
- Somers-Edgar TJ and Rosengren RJ. Coenzyme Q₀ induces apoptosis and modulates the cell cycle in estrogen receptor negative breast cancer cells, 33
- Sommer C. *See* Benesch M, 794
- Song CW. *See* Terai K, 901
- Song J. *See* Chen P, 141
- Speake G. *See* Rukazenzov Y, 856
- Sperduti I. *See* Nisticò C, 109
- Stadler W. *See* Lara Jr PN, 179
- Stemmler H-J. *See* Schulz C, 867
- Striano S. *See* Facchini G, 893
- Ströbel P. *See* Kripp M, 75
- Strobl JS. *See* Rahim R, 736
- Stroebel P. *See* Horisberger K, 519
- Stutchbury TK. *See* Locke JM, 822
- Subramaniam V. *See* Chakrabarti R, 334
- Sui J. *See* Tian G, 389; *also* Tian G, 403
- Sun B. *See* Chen H, 131
- Sun DS. *See* Zhang YK, 702
- Sun X. *See* Chen H, 131; *also* Zhang M, 355
- Sun Y *et al.* A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs, 757; *also*. Folate-bearing doxorubicin-loaded magnetic poly(*N*-isopropylacrylamide) microspheres as a new strategy for cancer therapy, 607
- Swaisland A. *See* Rukazenzov Y, 856
- Syrgos KN. *See* Syrigou E, 1
- Syrgou E *et al.* Hypersensitivity reactions to antineoplastic agents: an overview, 1
- Szalontay L. *See* Seitz S, 553
- Szepeshazi K. *See* Seitz S, 553
- Tahir SK. *See* Luo Y, 483
- Takubo K *et al.* Involvement of *N*-acetyltransferase human in the cytotoxic activity of 5-fluorouracil, 668
- Tanaka H. *See* Kimura T, 513
- Tang C *et al.* Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis, 249
- Tang J-j. *See* Ji Y, 832
- Tang S. *See* Sun Y, 607
- Tao W. *See* Zhang M, 355
- Tarabar D. *See* Aaron DuVall G, 89
- Tarpin C. *See* Gonçalves A, 946
- Teng Y. *See* Li D, 59; *also* Zhang Y, 208
- Terai K *et al.* Cisplatin enhances the anticancer effect of β -lapachone by upregulating NQO1, 901
- Terzoli E. *See* Nisticò C, 109
- Tesei A. *See* Vannini I, 918
- Testa U. *See* Petronelli A, 880
- Thorne RF. *See* Mhaidat MN, 601
- Tian G *et al.* A patient with huge hepatocellular carcinoma who had a complete clinical response to p53 gene combined with chemotherapy and transcatheter arterial chemoembolization, 403; *also*. Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial, 389
- Tian J. *See* Gao C, 807
- Tochino Y. *See* Kimura T, 513
- Torrise R. *See* Balduzzi A, 197
- Touquet B. *See* Martel-Franchet V, 469
- Treszl A. *See* Seitz S, 553
- Tropea F. *See* Nisticò C, 109
- Tseng S-Y. *See* Yu S-T, 382
- Tsuchiya H. *See* Takubo K, 668
- Tucker S. *See* He J, 838; *also* Li M, 941
- Turcotte É. *See* Beauparlant P, 346
- Turner J and Chaudhary U. Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer, 215
- Twardowski P. *See* Lara Jr PN, 179
- Uchino K. *See* Makiyama A, 123
- Ulivi P. *See* Vannini I, 918
- Umansky V. *See* Ramacher M, 910
- Umekawa K. *See* Kimura T, 513
- Urban C. *See* Benesch M, 794
- Vaccaro V. *See* Nisticò C, 109
- Valent F. *See* Minisini AM, 503
- van Berkel MPA. *See* Bijman MNA, 450
- van den Beuken-van Everdingen M. *See* Beijer S, 625
- van den Borne BE. *See* Beijer S, 625
- van den Brandt PA. *See* Beijer S, 625
- van Henten AM. *See* Beijer S, 625
- Vannini I *et al.* Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines, 918
- Vansant G. *See* Monks A, 682
- Veronesi P. *See* Balduzzi A, 197
- Viale G. *See* Balduzzi A, 197
- Viens P. *See* Gonçalves A, 946
- Vine KL. *See* Locke JM, 822
- Vispé S. *See* Kruczynski A, 364
- Vogel U. *See* Nissen KK, 174
- von Bueren AO. *See* Dedes KJ, 321
- von Hoff K. *See* Benesch M, 794
- von Weyhern C. *See* Pintoff J, 73
- Waldron-Lynch MG. *See* James E, 634
- Wang C *et al.* Effects of a novel tripeptide, tyrosineleutide (YSL), on cell cycle progression of human hepatocellular carcinoma, 534; *also see* Sun Y, 607
- Wang D. *See* He J, 838; *also* Li M, 941
- Wang F. *See* Cui X, 800; *also* Tang C, 249
- Wang JC. *See* Agheli A, 525
- Wang L-l. *See* Wang C, 534
- Wang S. *See* Wang C, 534
- Wang Y. *See* Sun Y, 757
- Watkins JF *et al.* Gemcitabine, irinotecan and celecoxib in patients with biliary cancer, 294
- Watson M. *See* Beauparlant P, 346
- Weber G. *See* Milla P, 396
- Wein A. *See* Wolff K, 165
- Wenz F. *See* Horisberger K, 519
- Wilkinson RW. *See* Rukazenzov Y, 856
- Willeke F. *See* Horisberger K, 519
- Williamson SK. *See* Watkins JF, 294
- Wo J. *See* Woodall CE, 437
- Woernle C. *See* Horisberger K, 519
- Wolff K *et al.* Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial, 165
- Woodall CE *et al.* Chemoprevention of metaplasia initiation and carcinogenic progression to esophageal adenocarcinoma by resveratrol supplementation, 437
- Wright AE. *See* Guzmán EA, 149
- Wu L. *See* Lim SH, 461
- Wu Q. *See* Celticki B, 787
- Wu Y. *See* Chen P, 141; *also* He J, 838
- Wu Y-m. *See* Ji Y, 832
- Xi T. *See* Tang C, 249
- Xi W. *See* Cao W, 287
- Xia S. *See* Li Y, 770
- Xiang XJ. *See* Zhao JG, 281
- Xie J-H. *See* Tang C, 249
- Xing Y-Y. *See* Tang C, 249
- Xiong JP. *See* Zhao JG, 281
- Xu B. *See* Zhang XY, 926
- Xu H. *See* Cui X, 800
- Xu J. *See* Li M, 941; *also* Li M, 941
- Xu K. *See* Chen P, 141
- Xu Q. *See* Wang C, 534
- Xu X. *See* He J, 838
- Xue X. *See* Chen P, 141
- Xun K. *See* Sun Y, 757
- Yagi Y. *See* Fushida S, 752
- Yamada H. *See* Abe A, 373
- Yamada R. *See* Oshima T, 312
- Yan J. *See* Zhao JG, 281
- Yang B. *See* Zhang L, 416
- Yang H. *See* He J, 838
- Yang J-S. *See* Tang C, 249
- Yang Q. *See* Zhang YK, 702
- Yang W. *See* Cao W, 287
- Yang X. *See* Zhang Y, 208
- Yang Y. *See* Qian H, 779
- Yao Z. *See* Wang C, 534
- Yde CW *et al.* The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells, 723
- Ying W. *See* He J, 838
- Ylikomi T. *See* Miettinen S, 267; *also* Miettinen S, 589
- Ylikomi TJ. *See* Pennanen PT, 51
- Yoshimura N. *See* Kimura T, 513
- Yu F. *See* Zhao JG, 281
- Yu J. *See* Sun Y, 607

- Yu S-T *et al.* Downregulation of GST π expression by tryptanthrin contributing to sensitization of doxorubicin-resistant MCF-7 cells through c-jun NH₂-terminal kinase-mediated apoptosis, 382
- Zamagni C. *See* Bianchi G, 616
- Zeillinger R. *See* Hamberger J, 559
- Zell JA. *See* Raj KP, 301
- Zhan Z. *See* Zhao JG, 281
- Zhang J. *See* Li D, 59; *also* Li M, 941; *also* Zhang L, 416; *also* Zhang Y, 208
- Zhang L *et al.* Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53–MDM2 interaction, 416; *also see* Zhao JG, 281
- Zhang M *et al.* Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts, 355; *also see* Gao C, 807
- Zhang XH. *See* Zhang YK, 702
- Zhang XY *et al.* Anticancer activity and mechanisms of diacetyldianhydrogalactitol on hepatoma QGY-7703 cells, 926
- Zhang Y *et al.* GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling, 208; *also see* Li D, 59
- Zhang YK *et al.* A proteomic study on a human osteosarcoma cell line Saos-2 treated with diallyl trisulfide, 702
- Zhang Y-p. *See* Ji Y, 832
- Zhao JG *et al.* A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer, 281
- Zhao L. *See* Wang C, 534
- Zhao S-H. *See* Chen P, 141
- Zhao T. *See* Cui X, 800
- Zhen Y-S. *See* Lin Y-J, 65; *also* hui H, 41
- Zhi X. *See* Sun Y, 607
- Zhong B. *See* He J, 838; *also* Li M, 941
- Zhong N. *See* He J, 838
- Zhou L. *See* Gao C, 807
- Zhou P. *See* Sun Y, 607
- Zhou R. *See* Tian G, 389
- Zhou S. *See* Cui X, 800
- Zhou X. *See* Zhang L, 416
- Zhou Y. *See* Zhang XY, 926
- Zhu L. *See* Chen P, 141
- Zhu Z-f. *See* Wang C, 534
- Zoldakova M. *See* Knauer S, 676
- Zoli W. *See* Vannini I, 918
- Zonato S. *See* Ferrari D, 185
- Zou J-N. *See* Tang C, 249